Page last updated: 2024-12-05

phenindamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Phenindamine is an antihistamine that was first synthesized in 1951 and marketed in 1958. It is a potent blocker of histamine H1 receptors, leading to its use in the treatment of allergic conditions such as hay fever, urticaria, and allergic rhinitis. Phenindamine acts as a sedative and exhibits anticholinergic effects, which are attributed to its interaction with muscarinic receptors. It also possesses anti-inflammatory properties due to its ability to inhibit the release of inflammatory mediators like prostaglandins and leukotrienes. Phenindamine has been studied for its potential in treating other conditions, such as motion sickness and Parkinson's disease. Research has explored its pharmacological mechanisms and its effectiveness in various clinical applications.'

phenindamine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID11291
CHEMBL ID278398
CHEBI ID8065
SCHEMBL ID29502
MeSH IDM0046968

Synonyms (53)

Synonym
1h-indeno[2,1-c]pyridine, 2,3,4,9-tetrahydro-2-methyl-9-phenyl-
2-methyl-9-phenyl-2,3,4,9-tetrahydro-1h-indeno[2,1-c]pyridine
phenindaminum [inn-latin]
2,3,4,9-tetrahydro-2-methyl-9-phenyl-lh-indeno(2,1-c)pyridine
phenindamine hydrochloride
nu 1504
fenindamina [inn-spanish]
1h-indeno(2,1-c)pyridine, 2,3,4,9-tetrahydro-2-methyl-9-phenyl-
brn 0221083
phenindamine [inn:ban]
einecs 201-443-4
2,3,4,9-tetrahydro-2-methyl-9-phenyl-1h-indeno(2,1-c)pyridine
PDSP2_000150
PDSP1_000151
82-88-2
C07790 ,
phenindamine
DB01619
thephorin
bdbm50089147
2-methyl-9-phenyl-2,3,4,9-tetrahydro-1h-indeno[2,1-c]pyridinium
chebi:8065 ,
nu-1504
CHEMBL278398 ,
2-methyl-9-phenyl-1,3,4,9-tetrahydroindeno[2,1-c]pyridine
L001053
phenindamine (inn)
D08353
5503-08-2
fenindamina
phenindaminum
772bq8ksst ,
5-20-08-00420 (beilstein handbook reference)
unii-772bq8ksst
phenindiamine
SCHEMBL29502
1,2,3,4-tetrahydro-2-methyl-9-phenyl-2-azafluorene
phenindamine [mi]
phenindamine [inn]
phenindamine [who-dd]
phenindamine [vandf]
2-methyl-9-phenyl-2,3,4,9-tetrahydro-1-pyridindene
2-methyl-9-phenyl-2,3,4,9-tetrahydro-1h-indeno[2,1-c]pyridine #
ISFHAYSTHMVOJR-UHFFFAOYSA-N
2,3,4,9-tetrahydro-2-methyl-9-phenyl-1h-indeno[2,1-c]pyridine
DTXSID0023452
2-methyl-9-phenyl-1h,2h,3h,4h,9h-indeno[2,1-c]pyridine
Q6583284
2-methyl-9-phenyl-2,3,4,9-tetrahydro-1-pyridindene; nu 1504; phenindamine; thephorin
NCGC00532494-01
EN300-18563900
CS-0017474
HY-A0149
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
indene
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Pathways (1)

PathwayProteinsCompounds
Phenindamine H1-Antihistamine Action87

Protein Targets (1)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Spike glycoproteinSevere acute respiratory syndrome-related coronavirusPotency5.62340.009610.525035.4813AID1479145
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Ceullar Components (1)

Processvia Protein(s)Taxonomy
virion membraneSpike glycoproteinSevere acute respiratory syndrome-related coronavirus
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID588220Literature-mined public compounds from Kruhlak et al phospholipidosis modelling dataset2008Toxicology mechanisms and methods, , Volume: 18, Issue:2-3
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
AID86244Inhibition of [3H]mepyramine binding with histamine H1 receptor in guinea pig cerebellum membranes after 30 min1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor.
AID86241Potency against histamine H1 receptor on guinea pig ileum1995Journal of medicinal chemistry, Aug-18, Volume: 38, Issue:17
The histamine H1-receptor antagonist binding site. A stereoselective pharmacophoric model based upon (semi-)rigid H1-antagonists and including a known interaction site on the receptor.
AID86584In vitro antagonistic activity at the Histamine H1 receptor in guinea pig ileum2000Bioorganic & medicinal chemistry letters, Jun-05, Volume: 10, Issue:11
Conformationally-restricted ligands for the histamine H1 receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (54)

TimeframeStudies, This Drug (%)All Drugs %
pre-199049 (90.74)18.7374
1990's3 (5.56)18.2507
2000's2 (3.70)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 37.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index37.84 (24.57)
Research Supply Index4.13 (2.92)
Research Growth Index3.96 (4.65)
Search Engine Demand Index45.04 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (37.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (1.67%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other59 (98.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]